

# Drug targeting alleviation of symptoms in AD patients

**Field of use**  
Veterinary medical Sciences

**Current state of technology**  
Preclinical studies

**Intellectual property**  
EP3256128 (B1),  
US10071964 (B2), SI24951(A)


**Developed by**  
University of Ljubljana,  
Faculty of Pharmacy

**Reference**  
UL20150787007

**Contact**  
Knowledge Transfer  
Office

Gabriela Droga Mazovec  
Phone: +386 1 241 85 83  
E-mail: ipr@uni-lj.si

ppz.uni-lj.si



## Background

Disturbances in memory and cognitive function, characteristic of patients with Alzheimer's disease are the result of a severely reduced concentration of the acetylcholine transporter in the brain. Inhibition of acetylcholine hydrolysis in the brain is used to increase acetylcholine concentration and subsequently alleviate memory disorders, restore cognitive function, and relieve symptoms of Alzheimer's disease and similar dementias.

## Description of the invention

The drug we have developed inhibits the hydrolysis of acetylcholine in the brain, alleviating symptoms in dogs suffering from canine cognitive impairment, which is dementia-like Alzheimer's disease. The present invention is being tested in dogs with symptoms of AD-like dementia and our goal is to market the drug for veterinary use and further test it for human use.

## Main advantages

Drugs developed to target Alzheimer's disease typically cause cholinergic side effects. In consequence, limited dosage may lead to decreased efficacy in later stages of the disease. The current drug works through a different mechanism of action, limiting the mentioned side effects and additionally can function in later stages of Alzheimer's disease.